Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its pipeline, citing strategic reasons unrelated to the asset’s safety or efficacy.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its pipeline, citing strategic reasons unrelated to the asset’s safety or efficacy.